ImmunoPrecise Antibodies Ltd. (OTCMKTS:IPATF – Get Free Report) traded up 2.3% on Friday . The stock traded as high as $1.35 and last traded at $1.35. Approximately 161,767 shares changed hands during trading, an increase of 696% from the average daily volume of 20,327 shares. The stock had previously closed at $1.32.
ImmunoPrecise Antibodies Stock Performance
The business has a 50-day simple moving average of $1.39 and a 200-day simple moving average of $1.36.
ImmunoPrecise Antibodies Company Profile
ImmunoPrecise Antibodies Ltd (OTCMKTS:IPATF) is a Canada-based contract research organization specializing in the discovery and development of therapeutic antibodies. The company provides a full suite of preclinical research services, from target validation and lead identification through to humanization and optimization. Its capabilities encompass hybridoma, phage display, single B cell sorting and next-generation sequencing platforms to accelerate antibody candidate selection and characterization.
ImmunoPrecise serves biopharmaceutical and biotechnology partners worldwide, offering customized solutions for projects in immuno-oncology, infectious diseases, autoimmunity and other therapeutic areas.
Recommended Stories
- Five stocks we like better than ImmunoPrecise Antibodies
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for ImmunoPrecise Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoPrecise Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.
